Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.

Estrogen alone may effectively suppress testosterone in some transfeminine individuals.

Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.

The review highlights the need for more research on transgender dermatology, the role of dermatologists in gender affirmation, and the effects of hormone therapy on skin and hair.

Estrogen alone can lower testosterone in some transfeminine people.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

Inclusive and culturally competent healthcare is crucial for transgender and non-binary individuals.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

Female authorship in dermatology publications increased during the COVID-19 pandemic, but women are still underrepresented in senior roles.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

Exogenous testosterone use may be linked to developing hidradenitis suppurativa.

Women may need different blood pressure guidelines than men for heart disease prevention.

The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.

Gender-affirming dermatology treatments generally improve mental well-being for transgender individuals, but more research is needed.

The transgender community in India has specific skin care needs and struggles to access dermatological services due to discrimination and financial issues.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

The conclusion is that recognizing the difference between gender identity and biological sex is crucial in dermatology to improve patient care and research accuracy.

Hair transplants help transgender patients look more like their gender identity, with different procedures for trans women and men.

Gender affects hair and scalp characteristics, with differences in hormone responses, graying patterns, and trace metals.

More research is needed to improve lower body gender affirmation techniques.

Hormone therapy and surgeries for transgender individuals affect their skin and hair, requiring specific dermatologic treatments and respectful care.

BMI is not a significant predictor of complications after gender-affirming penile inversion vaginoplasty.

The document concludes that facial feminization surgery improves psychological well-being and social acceptance for transgender individuals.

Non-surgical treatments can significantly reduce keloids in children, with combination therapies being safer and more effective.

Pediatric endocrinologists should provide early fertility counseling and preservation options to young patients at risk of infertility.

Facial contouring is crucial for the satisfaction and well-being of Chinese transgender females.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

Proper planning and technique in upper-face feminization surgery are crucial to avoid complications and revisions.

Androgen treatment with dihydrotestosterone may help maintain height in patients with 5-α-reductase type 2 deficiency, especially before puberty.